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Summary
The initiating events that promote tau mislocalization and pathology in Alzheimer’s disease (AD) 
are not well defined, due partly to the lack of endogenous models that recapitulate tau dysfunction. 
We exposed wild-type neurons to a neuroinflammatory trigger and examined the impact on 
endogenous tau. We found that tau re-localized and accumulated within pathological neuritic foci, 
or beads, comprised of mostly hypo-phosphorylated, acetylated, and oligomeric tau. These 
structures were detected in aged wild-type mice and were enhanced in response to 
neuroinflammation in vivo, highlighting a previously undescribed endogenous age-related tau 
pathology. Strikingly, deletion or inhibition of the cytoplasmic shuttling factor HDAC6 suppressed 
neuritic tau bead formation in neurons and mice. Using mass spectrometry-based profiling, we 
identified a single neuroinflammatory factor, the metalloproteinase MMP-9, as a mediator of 
neuritic tau beading. Thus, our study uncovers a link between neuroinflammation and neuritic tau 
beading as a potential early-stage pathogenic mechanism in AD.
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Introduction
Tau proteins, which comprise six distinct tau isoforms in the brain, normally act to bind and 
stabilize neuronal microtubules (MTs) (Andreadis, et al. 1992; Goedert, et al. 1989). The 
regulation of tau binding to MTs is dependent on serine/threonine phosphorylation 
predominantly in the proline-rich region and also by lysine acetylation directly within the 
MT-binding repeat region (MTBR). These two post-translational tau modifications act in 
concert to decrease tau-MT binding affinity (Biernat, et al. 1993; Bramblett, et al. 1993; 
Drechsel, et al. 1992). While tau hyper-phosphorylation has been extensively characterized 
in association with neurofibrillary tangle (NFT) pathology in Alzheimer’s disease (AD), the 
role for tau acetylation in neurons is not fully understood. However, recent studies indicate 
that acetylated tau alone is sufficient to promote tau aggregation, synapse degeneration, and 
cognitive deficits in tauopathies (Min, et al. 2015; Tracy, et al. 2016).
Site-specific tau acetylation has been identified spanning the MTBR domain (Morris, et al. 
2015). Recent studies showed that acetylation occurs within and adjacent to the MTBR 
including K174, K274, K281 that can lead to tau-induced toxicity (Min, et al. 2015; Tracy, 
et al. 2016). Our previous studies showed a striking accumulation of acetylated tau at residue 
K280 (located in the 2nd MTBR) in AD patients and a wide spectrum of other human 4-
repeat (4R) tauopathies including corticobasal degeneration (CBD) and progressive 
supranuclear palsy (PSP) (Cohen, et al. 2011). While tau K280 acetylation is an excellent 
marker of AD progression that correlates with thioflavin-positive mature neurofibrillary 
tangles (NFTs), we detected limited tau acetylation in wild-type cultured neurons or control 
human brain tissue, suggesting tau acetylation may selectively accumulate in response to 
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specific neurotoxic cues that remain to be identified (Cohen, et al. 2011; Irwin, et al. 2012). 
Most tau toxicity studies rely on tau over-expression paradigms rather than modeling 
endogenous tau pathology. A better understanding of the initiating events that trigger early-
stage endogenous tau pathogenesis will provide new avenues to prevent dysfunction in AD 
and related tauopathies.
Some of the very earliest neuronal dysfunction in AD includes calcium dysregulation and 
the development of focal neuritic beads (also known as swellings or varicosities) within 
axons and dendrites (Falzone and Stokin 2012; Hall, et al. 2000; Pike, et al. 1992; Sanchez-
Varo, et al. 2012; Stokin, et al. 2005; Takeuchi, et al. 2005). While Aβ plaques and NFTs are 
the most well-established hallmark features of AD, focal beading is also a prominent yet 
poorly understood marker of neuronal damage that occurs in a range of neurodegenerative 
diseases including AD (Xiao, et al. 2011), Parkinson’s disease (PD) (Tagliaferro and Burke 
2016), amyotrophic lateral sclerosis (ALS) (Delisle and Carpenter 1984; Okamoto, et al. 
1990), traumatic brain injury (Johnson, et al. 2013), and normal brain aging (Geula, et al. 
2008). Neuritic beading is also induced by neurotoxic stimuli such as glutamate (Hosie, et 
al. 2012; Kim, et al. 2010), nitric oxide (NO) (He, et al. 2002), hypoxia (Scott, et al. 2002), 
oxidative stress (Roediger and Armati 2003), and membrane shearing (Kilinc, et al. 2009).
Prior studies indicate that neuritic beading correlates with excitotoxicity and degenerating 
synapses in AD (Greenwood, et al. 2007; Takeuchi, et al. 2005; Tan, et al. 2007). For 
example, neuritic beading is suppressed by pharmacological inhibition of NMDA receptors 
(NRs) (e.g. MK801 or AP5) or by intracellular calcium chelators (e.g. EDTA) (Kim, et al. 
2010; Takeuchi, et al. 2005), supporting an NR-mediated process. While a functional role 
for tau in neuritic bead formation has not been characterized, mislocalized tau was shown to 
mediate NR activation through dendritic recruitment of the kinase Fyn (Ittner, et al. 2010; 
Roberson, et al. 2011). Tau-Fyn mislocalization to the dendritic compartment facilitates NR-
subunit phosphorylation (Ittner, et al. 2010; Zempel, et al. 2010). Indeed, reducing tau or 
Fyn levels alleviated hyper-excitability and neurotoxicity in models of AD or traumatic brain 
injury (Cheng, et al. 2014; Kaufman, et al. 2015; Roberson, et al. 2011; Roberson, et al. 
2007). Thus, two seemingly distinct pathological phenomenon, neuritic bead formation and 
tau mislocalization, are implicated as triggers for excitotoxicity in AD. Whether these two 
events are coordinated to mediate neuronal dysfunction is unknown.
Here, we used Aβ oligomer-challenged macrophages and microglia to generate conditioned 
media containing neuroinflammatory factors in order to assess the downstream effects on 
endogenous neuronal tau. Surprisingly, we found that tau re-localized to neuritic bead-like 
foci that showed features of AD pathology. Inhibiting or depleting the tau-associated 
deacetylase HDAC6 suppressed tau mislocalization and neuritic bead formation. Overall, 
our study describes a mechanism that connects neuroinflammation to focal tau accumulation 
as a potential early-stage tau pathology that emerges prior to the development of overt NFTs.
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Results
Aβ-oligomer induced neuroinflammatory stress promotes neuritic tau-immunoreactive 
beading
We considered the possibility that neuroinflammation present in the brains of tau transgenic 
(PS19) mice and human AD brain, but not in isolated neuronal cultures, could potentially 
explain the striking tau mislocalization and acetylation patterns observed in vivo. Thus, we 
examined Aβ oligomer-induced neuroinflammation as a plausible mediator of endogenous 
tau dysfunction. Synthetic Aβ1–42 oligomers were generated and confirmed by three 
independent methods: the appearance of multimeric Aβ species, A11 oligomer 
immunoreactivity, and dynamic light scattering (DLS) (Figure S1). Human monocyte-
derived macrophages (referred to as hMDM) were challenged with Aβ oligomers and cell 
morphology was monitored. We used the lowest non-toxic Aβ oligomer concentration (1 
μM) capable of activating immune cells in vitro (Dhawan, et al. 2012). Aβ oligomer 
stimulation increased the appearance of podosome-bearing cells compared to ruffled and 
non-specialized cells. Such a conversion was previously shown to correlate with secretion of 
neurotoxic factors (Williams, et al. 2015). Quantification of this morphology transformation 
showed a significant increase in podosome containing cells after 24 hr Aβ oligomer 
stimulation (Figure S1). Thus, in an analogous manner to HIV virion particles (Meeker, et 
al. 2016), Aβ oligomers were sufficient to generate conditioned media (hereafter referred to 
as Aβ-CM) that was subsequently evaluated for its pathogenic effects on cultured neurons.
Primary cortical neurons were exposed to Aβ-CM and tau localization was assessed using a 
panel of well-characterized tau antibodies (Figure 1A and Table S1). Surprisingly, Aβ-CM 
derived from either hMDM or microglia (the latter designated as mAβ-CM) induced the 
accumulation of tau within distinct neuritic beads that were detected with the 
dephosphorylation-specific tau-1 antibody (Figure 1A), which were not detected in tau KO 
neurons (Figure S2). We note that conditioned media generated by other inflammatory cues 
(e.g. HIV virion particles) can also induce neuritic tau beading (Figure S3). We refer to these 
structures as tau-1 immunoreactive (tau-1IR) foci or beads. Quantification of tau-1IR beading 
showed a significant ~ 12-fold induction in response to Aβ-CM (Figure 1B). Endogenous 
mouse tau detected with T49, K9JA, or tau-5 antibodies was also localized to distinct 
neuritic foci, although the tau-1 antibody appears to have slightly higher affinity and 
detection sensitivity for these structures. In contrast, we observed limited neuritic 
immunoreactivity with the phospho-tau AT8 (S202/T205) antibody, which is commonly 
used to mark tau pathology in AD. To confirm that the observed beading is due to Aβ-CM 
and not residual Aβ oligomers present in the conditioned media, Aβ oligomers (AβO, 1 μM) 
were added directly to neurons (Figure 1A and 1B), which did not induce significant 
morphological changes. These results suggest that secreted neuroinflammatory factors 
produced in the Aβ-CM are responsible for tau re-localization and accumulation within 
neuritic beads.
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Neuritic tau beads are comprised of site-specific phosphorylated, acetylated, and 
oligomeric tau
We next analyzed additional acetylated and phosphorylated tau epitopes known to 
accumulate in AD brain. While tau K280 acetylation is not normally detected in wild-type 
neurons, tau beads were strikingly immunoreactive with ac-K280 (Figure 1C), a disease-
specific marker of tauopathy (Cohen, et al. 2011). Despite the fact that AT8 was negative, 
neuritic beads were phosphorylated at an adjacent epitope (S199) in the proline-rich region 
(Figure 1D) and also within the MTBR (S262), a preferred MARK2 phosphorylation site 
(Figure 1E) (Drewes, et al. 1997). Further supporting MARK2 involvement, active MARK2 
detected with a phospho-MARK antibody (residue T208) was present within tau beads, 
albeit less abundant compared to its phospho-tau S262 target site (Figure 1F). Both K280 
acetylation and S262 phosphorylation have been implicated in dissociation of tau from MTs 
(Cohen, et al. 2011; Schwalbe, et al. 2013), suggesting tau beading coincides with loss of 
normal tau-MT binding. We next examined oligomeric tau, an indicator of early-stage tau 
pathology (Lasagna-Reeves, et al. 2012), using the T22 antibody and found that it was 
highly enriched within neuritic tau-1IR beads (Figure 1G, see quantification in Figure 1H).
We further analyzed a panel of dendritic markers implicated in aberrant tau-mediated 
neuronal hyper-excitability. Neuritic tau beads co-localized with the dendritic marker 
MAP2, the tau kinase Fyn implicated in tau recruitment to the dendritic compartment, as 
well as NR1, a major NMDA receptor subunit that is subject to phosphorylation-dependent 
activation and excitotoxicity (Ittner, et al. 2010; Roberson, et al. 2011) (Figure S4). We also 
examined the localization of other factors involved in protein quality control including 
autophagy and ubiquitin-proteasome system (UPS) components that regulate tau processing 
and triage. The deacetylase HDAC6, an adaptor protein that detects and shuttles misfolded 
proteins (Kawaguchi, et al. 2003) and also binds and deacetylates tau (Cohen, et al. 2011; 
Ding, et al. 2008; Perez, et al. 2009), strongly localized to most tau-1IR beads (Figure 2A). 
Similarly, the E3 ligase CHIP and the 20S proteasome, implicated in tau processing, were 
localized to neuritic beads, while autophagosomal markers such as LC3 were not 
prominently detected within these structures (Figure S4). Overall, our analysis indicates that 
tau beads recruit a variety of axonal and dendritic factors known to interact with and process 
tau.
HDAC6 depletion or inhibition suppresses neuritic bead formation
We sought to identify a mechanism by which neuritic tau beads form in vulnerable neurons. 
Given the robust recruitment of HDAC6 to tau-1IR beads, we asked whether manipulating 
HDAC6 levels or activity would alter tau beading in Aβ-CM treated neurons. We used 
HDAC6 KO neurons (Figure 2B) as well as pharmacological exposure of wild-type neurons 
to tubastatin A (TBST), a selective HDAC6 inhibitor (Figure S5). Remarkably, elimination 
of HDAC6 showed nearly a complete loss of neuritic tau beads (Figure 2B) as well as 
reduced focal recruitment of degradative and synaptic components to bead-like structures 
(Figure 2C–E). Overall there was a ~ 90% reduction in tau beading in HDAC6 KO neurons 
(Figure 2F), supporting HDAC6-dependent neuritic bead formation. A similarly dramatic 
suppression of beading was observed with TBST treatment (Figure 2F and Figure S5).
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To investigate the physiological consequences of tau beading, we assessed the viability of 
neurons challenged with Aβ-CM in the presence or absence of TBST. Using independent 
survival assays that monitor neuronal death or metabolic function, we found that TBST 
partially alleviated only the neuronal death phenotype as assessed by LDH assay, but did not 
significantly alter the reduction in metabolic activity assessed by MTT assays (Figure 2G), 
suggesting a neuroprotective effect that is independent of mitochondrial function. 
Surprisingly, mild neuroprotection occurred despite the fact that tau acetylation levels were 
increased in neurons exposed to TBST (Figure S5).
Since neuronal death in AD is linked to excitotoxicity, we asked whether tau-1IR bead 
formation is associated with intracellular calcium increases that occur following NR 
activation. Live calcium imaging was performed in Aβ-CM challenged neurons in the 
absence or presence of TBST to suppress tau-1IR beading (Figure 3). Excitotoxicity is 
associated with delayed and sustained elevation of intracellular calcium, and we therefore 
monitored both the early acute and delayed calcium changes occurring over a ~ 60 min 
period following exposure to Aβ-CM. Aβ-CM induced an acute calcium rise in the neuronal 
cytoplasm followed by a gradual delayed calcium increase (Figure 3A). Notably, discrete 
foci of calcium accumulation were seen in axonal and dendritic processes, which gave rise 
to neuritic beads (Figure 3A, see white arrowheads at 10, 30, and 60 min time-points). 
Conditioned media generated from Aβ-challenged hMDM (Aβ-CM), Aβ-challenged 
microglia (mAβ-CM), or even HIV virion-challenged hMDM (HIV-CM) induced 
comparable calcium dysregulation in neurons (Figure 3B and Figure S3). HDAC6 KO or 
TBST treatment dramatically reduced calcium influx throughout the incubation period by ~ 
4–5 fold, including at the endpoint of the delayed calcium phase (Figure 3B and 3C). The 
calcium influx and beading were also strongly inhibited by the NMDA receptor antagonist 
AP5, suggesting that tau-1IR beads represent active sites of NMDA-receptor driven calcium 
influx. In contrast, inhibition of MARK2 (also localized to neuritic beads, Figure 1F) using 
MARK inhibitor 39621 did not affect calcium influx (Figure 3C).
We next assessed the impact of Aβ-CM on tau by immunoblotting using a panel of tau 
antibodies (Figure S5). Total tau levels were not appreciably altered in Aβ-CM challenged 
neurons, consistent with tau mislocalization as a key pathological indicator, as opposed to 
changes in overall tau stability. Tau hypo-phosphorylation was observed at most phospho-tau 
epitopes including AT180 (T231) and AT270 (T181) in response to Aβ-CM, and this effect 
that was partially restored by inhibition of neuritic beading with either TBST or AP5. 
Furthermore, levels of acetylated tubulin, a marker of stable microtubules, were also restored 
by TBST. Thus, we conclude that neuroinflammatory factors stimulate HDAC6-dependent 
tau re-localization, tau hypo-phosphorylation at most common pathological tau epitopes, and 
the formation of axonal and dendritic tau-1IR beads.
In vivo neuritic tau-1IR pathology in mouse and human brain
We considered whether the neuritic tau-1IR species detected above could be recapitulated in 
vivo. Although endogenous tau pathology is not typically detectable in normal wild-type 
mice, we asked whether tau-1IR pathology might accumulate as a consequence of aging, the 
major risk factor for AD. In contrast to young mice that showed faint diffuse axonal tau-1 
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staining patterns throughout the brain, aged 27 month old mice showed a striking 
accumulation of tau-1IR foci that were concentrated as distinct patches or clusters 
throughout the hippocampus, particularly in CA1, and distributed more selectively 
throughout cortical brain regions (Figure 4A). Tau-1 immunoreactive clusters gradually 
accumulated with age, as assessed by immunoblotting (Figure 4B), immunofluorescence 
(Figure 4C), and immunohistochemistry (Figure 4D). These structures became more readily 
detectable starting around 12 months old (see quantification in Figure 4E).
We examined whether a neuroinflammatory challenge could modulate tau-1 
immunoreactivity in vivo in a manner similar to our observations in vitro using Aβ-CM 
(Figure 1). We employed a lipopolysaccharide (LPS) injection paradigm in which a single 
LPS dose (5 mg/kg) given to young 3-month old mice was sufficient to induce chronic long-
term neuroinflammation up to 10 months post LPS injection (Qin, et al. 2007). We observed 
a significant increase in tau-1IR pathology in LPS-stimulated mice compared to age-matched 
saline injected controls (Figure 4F, see quantification in Figure 4G). Thus, tau-1IR pathology 
accumulates as a general feature of normal brain aging that can be significantly accelerated 
by neuroinflammatory cues.
To examine the nature of tau-1IR clusters in vivo, double-labeling of aged mouse brain 
sections was performed with tau-1 and either ac-K280, T22, or MAP2 antibodies, all of 
which detected neuritic tau beads in vitro. Similarly, in vivo tau-1IR clusters were ac-K280-
positive, strongly T22-immunoreactive, and also partially accumulated in the dendritic 
compartment as assessed by co-localization with MAP2 (Figure 5A). We note that these 
structures are labeled with the same antibodies that detected tau-1IR foci in vitro, and are not 
AT8-immunoreactive or detectable by standard Thioflavin-S staining (Figure S6). Tau-1IR 
pathology in mouse brain therefore appears to represent a biochemically distinct age-related 
tau species. Similar to HDAC6-mediated tau beading in vitro (Figure 2), tau-1IR clusters 
were suppressed in the brains of HDAC6 KO mice (Figure 5B, see quantification in Figure 
5C). The reduced tau-1IR pathology could potentially explain the restored cognitive function 
observed with HDAC6 depletion or inhibition (Govindarajan, et al. 2013; Selenica, et al. 
2014; Zhang, et al. 2014).
Hyper-phosphorylated tau (e.g. AT8 immunoreactive tau) is commonly used to monitor tau 
pathology in human AD brain. In contrast, dephosphorylated tau-1IR pathology, an epitope 
that overlaps with AT8, has not been well studied in postmortem tissue. However, since Aβ 
facilitated the formation of tau-1IR pathology in vitro, we asked whether tau-1 
immunoreactivity was associated with Aβ plaque pathology in AD brain. We performed 
double-labeling with the tau-1 antibody and Thioflavin S (ThS), the latter of which robustly 
marked AD neuritic plaques and thread-like tau pathology. Indeed, tau-1 immunoreactivity 
was clearly detected in a subset of neuritic plaques and tau inclusions in AD brain. As a 
control, neuritic plaques were immunoreactive with the Aβ-specific 6E10 antibody (Figure 
6A).
To further confirm tau-1IR pathology using biochemical methods, we performed a sequential 
extraction of frontal cortex from control and AD brains and analyzed soluble and insoluble 
tau species by immunoblotting (Figure 6B). We observed a reduction of tau-1 
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immunoreactivity in soluble high-salt fractions and a concomitant increase in the insoluble 
tangle-rich fractions (i.e. tau aggregate smearing), consistent with a conversion towards 
tau-1-positive pathology. While insoluble tau was also hyper-phosphorylated at other AD-
relevant epitopes (e.g. S396 and S262), the phospho-tau immunoreactive banding patterns 
were distinct; they tended to show high and low molecular weight smearing compared to the 
tau-1 immunoreactive bands that migrated preferentially as monomeric tau species (Figure 
6B, see asterisk). Thus, in contrast to global tau hyper-phosphorylation, dephosphorylated 
tau-1IR pathology represents a significant pool of total pathological tau in AD brain.
Identification of neurotoxic factors linked to neuritic tau beading
Given that Aβ-CM likely consists of a mixture of secreted pro- and anti-inflammatory 
immune factors (Williams, et al. 2015), we sought to identify the neurotoxic factor(s) 
responsible for tau beading and excitotoxicity. To accomplish this, we profiled Aβ-CM using 
a mass spectrometry (MS)-based label-free quantitative (LFQ) approach. We identified a 
total of 1472 proteins, among which 817 proteins were identified with at least 2 unique 
peptides (Table S2). The volcano plot demonstrates significance (−logP) and changes that 
occurred in response to Aβ oligomers (Figure 7A, displayed as log2 Aβ/untreated). Overall, 
354 proteins increased and 258 proteins decreased with false-discovery-rates (FDR) < 5%. A 
biological function (DAVID) analysis of the 354 significantly induced hits identified factors 
that were enriched in immune and inflammatory responses as well as neuronal stress and 
apoptotic signaling pathways (Figure 7B). Further cluster analysis identified two large 
networks of proteins with shared functions in neuroinflammation and metabolism (Figure 
S7).
Among the immune factors identified in Aβ-CM, a set of matrix metalloproteinases 
(MMP-1, -7, and -9) were significantly altered, consistent with prior reports linking 
extracellular MMP activity to AD progression (Mroczko, et al. 2013; Nubling, et al. 2012; 
Stomrud, et al. 2010) (Figure 7A and Figure S7). Since MMP-9 levels were previously 
shown to increase in AD patient CSF (Stomrud, et al. 2010) as well as iPSC cell culture 
models of mutant tau-induced frontotemporal dementia (FTD) (Biswas, et al. 2016), we 
focused on MMP-9 as a candidate factor that may partially mediate the effects of Aβ-CM on 
tau. In contrast to most MMP family members, MMP-9 contains gelatinase activity, which is 
readily detected by SDS-PAGE gels supplemented with gelatin. Serial analysis of undiluted 
Aβ-CM detected increased gelatinase activity migrating ~ 75–100 kD (Figure 7C, top 
panel), indicating Aβ oligomers induced secretion of MMP-9. Moreover, direct 
immunoblotting of Aβ-CM with an MMP-9 specific antibody also detected active secreted 
MMP-9 that was not observed in the absence of Aβ oligomer stimulation (Figure 7C, bottom 
panel).
To test the effect of MMPs on neuritic beading, recombinant purified MMP-7 or MMP-9 
were directly added to neuronal cultures. The final exposure concentration of MMP-9 (5 
ng/ml) reflected known physiological MMP-9 concentrations in cerebrospinal fluid (CSF) 
(Ichiyama, et al. 2009). While MMP-7 had little effect on focal neuritic tau beading, MMP-9 
generated tau-1IR foci that were similar, although less pronounced, compared to complete 
Aβ-CM (Figure 7D, see quantification, right panel), suggesting MMP-9 can partially 
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recapitulate neuritic tau beading. To further evaluate whether MMP-9 induced calcium 
deregulation, live imaging was performed after recombinant MMP-9 addition to neurons, 
which showed an increase in the rate and intensity of calcium spikes (Figure 7E), consistent 
with previous reports that MMP-9 is coupled to NMDA receptor activation (Michaluk, et al. 
2009). The net effect of MMP-9 was a mild accumulation of intracellular calcium that 
recapitulated the pattern, but not the full intensity, of the response to Aβ-CM. These data 
suggest that MMP-9 is sufficient to increase the vulnerability of neurons to the development 
of tau-1IR pathology but is not solely responsible. Importantly, the MMP-9-mediated 
calcium increase was dependent on HDAC6 activity, as TBST significantly blunted calcium 
spiking by ~ 3-fold (Figure 7E, right panel). Finally, to assess the impact of MMP-9 loss of 
function, we incubated Aβ-CM with an MMP-9-specific inhibitor prior to calcium imaging 
and we observed a ~50% reduction in the acute phase calcium rise (Figure 7F). Thus, our 
proteomics approach uncovered a single neuroinflammatory factor, MMP-9, as one upstream 
mediator in the pathological cascade leading to HDAC6-dependent tau-1IR beading and 
calcium dysregulation.
Discussion
In this study, we show that tau accumulation within neuritic beads is an endogenous 
neuronal response to inflammatory perturbations. In a search for mediators of neuritic bead 
formation, we identified the cytoplasmic deacetylase HDAC6 as a shuttling factor required 
for tau re-localization and calcium-mediated excitotoxicity. Further in vivo analysis of 
neuritic tau beading revealed tau-1IR clusters in hippocampal and cortical regions of aged 
wild-type mice, supporting the accumulation of dephosphorylated tau (at the tau-1 epitope) 
as a plausible early-stage indicator of neuronal damage and/or vulnerability that precedes 
overt tangle formation. Our data indicate that acetylated, hypo-phosphorylated, and 
oligomeric tau accumulates at sites of focal calcium signaling in vulnerable neurons and 
could represent a unique tau species that is primed to undergo subsequent maturation and 
pathological aggregation during normal aging or the progression of AD.
Toxic Aβ induces a neuroinflammatory signature that coincides with synaptic degeneration. 
However, most in vitro neuronal models have not considered the impact of Aβ on 
neuroinflammation, potentially under-estimating its effects on neuronal dysfunction. Our 
analysis of the Aβ-induced secretome by mass spectrometry identified a subset of secreted 
MMPs among which MMP-9 partially recapitulated tau foci formation and calcium 
dysregulation. While the exact role for MMP-9 in AD pathogenesis is not fully understood, 
MMP-9 is implicated in neuronal activity through the activation of integrin β1 leading to 
phosphorylation of NMDA receptor subunits (Michaluk, et al. 2009). MMP-9 levels are up-
regulated in AD and during epileptogenesis characterized by hyper-excitability and aberrant 
NR activity (Stomrud, et al. 2010; Wilczynski, et al. 2008). Thus, MMP-9 may be coupled to 
tau dysfunction similar to other excitotoxic stimuli including, for example glutamate-
induced excitotoxicity, which also promotes tau hypo-phosphorylation (Davis, et al. 1995). 
Future studies are necessary to determine the mechanism by which extracellular MMP-9 
facilitates intracellular tau mis-localization.
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Tau is thought to represent ~ 0.025–0.25% total brain protein (Khatoon, et al. 1992). Thus, 
MT-dissociated tau requires quality-control mechanisms including proteasome and 
autophagy-dependent pathways to maintain proteostasis. In healthy neurons, the adaptor 
protein HDAC6 may bind tau and actively shuttle tau for targeted sequestration or 
degradation. Prior studies showed direct tau-HDAC6 binding via the tau MTBR domain 
(Ding, et al. 2008; Perez, et al. 2009). While HDAC6 is known to bind ubiquitinated cargo, 
it remains unclear whether tau-1IR beads are active sites of tau triage and/or degradation. We 
have not observed tau ubiquitination or degradation upon treatment with Aβ-CM, despite the 
fact that 20S proteasomes were partially concentrated within tau-1IR beads (Figure S4). 
Alternatively, HDAC6 deacetylates and regulates a variety of cytoplasmic factors including 
MTs and heat shock proteins (e.g. HSP70 and HSP90) that also directly interact with tau 
(Yan 2014). Therefore, HDAC6 could shuttle tau to neuritic beads indirectly via regulation 
of tau-associated adaptor, scaffolding, and/or structural proteins (e.g. actin and MTs). 
Finally, HDAC6 also shuttles to the nucleus and regulates gene transcription (Bertos, et al. 
2004; Verdel, et al. 2000). Thus, it remains plausible that inhibition of HDAC6 nuclear 
function could partly contribute to the suppression of tau beading and excitotoxicity.
Our data suggest that under neuroinflammatory conditions HDAC6-associated complexes 
could become trapped within the damage-induced neuritic beads. The presence of HDAC6 
initially suggested active deacetylation of tau, but in contrast, we observed increased K280-
acetylated tau within beads. Therefore, we speculate that HDAC6 activity may become 
impaired within the dense beaded network along with other trapped vesicles and degenerated 
cytoskeletal components, eventually leading to increased tau acetylation, NR activation, and 
calcium deregulation. Increased intracellular calcium accumulation could further exacerbate 
neuronal toxicity via activation of downstream calcium-dependent enzymes including 
calpain and calcineurin, both of which have been implicated in Aβ-induced neurotoxicity 
(Kurbatskaya, et al. 2016; Rozkalne, et al. 2011).
Prior studies indicated that acetylated tau impairs tau-MT binding and enhances tau 
aggregation, toxicity, and synaptic dysfunction (Cohen, et al. 2011; Min, et al. 2015; Tracy, 
et al. 2016). This is supported by our previous inability to detect robust tau K280 acetylation 
in normal cultured neurons or control brain tissue and by our current data showing that 
neuroinflammatory stress may act as a trigger for the accumulation of acetylated tau (Figure 
1C). We speculate that tau acetylation is pathogenic when highly concentrated within 
neuritic beads, which could facilitate its aggregation or perturb the cytoskeleton and 
associated synaptic factors including, for example, the recently described KIdney/BRAin 
protein (KIBRA) (Tracy, et al. 2016). By blocking HDAC6-dependent neuritic bead 
formation, aberrantly modified tau may not have similarly pathogenic consequences. Indeed, 
HDAC6 inhibition mildly induced tau acetylation (Figure S5), but this was coincident with a 
partial suppression of neurotoxicity (Figure 2G), suggesting enhanced tau acetylation does 
not necessarily correlate with neurotoxicity. A tau acetyltransferase(s) such as CBP/p300 
could localize to tau beads to facilitate tau acetylation. Alternatively, local acetyl co-A 
accumulation within or surrounding beaded structures may be sufficient to promote tau auto-
acetylation and drive tau aggregation in a localization and concentration-dependent manner 
(Cohen, et al. 2013).
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In contrast to tau acetylation, tau hyper-phosphorylation was not prominently detected 
within neuritic beads, at least at several of the phospho-tau epitopes examined. This is 
supported by other studies showing that acetylated tau at residues K274 and K281 led to 
neurotoxicity and synaptic defects with little apparent hyper-phosphorylation at AD-relevant 
epitopes (Tracy, et al. 2016). Thus, hypo-phosphorylated yet acetylated tau could initially 
mark early-stage mislocalized tau followed by later stage tau hyper-phosphorylation, a step-
wise modification scheme that may be required for maturation of tau aggregates into NFTs. 
We propose that tau-1 immunoreactive pathology could occur as an initial compensatory 
response in healthy, yet vulnerable neurons, which could reflect adequate PP2A activity and 
hence sufficient tau dephosphorylation until a certain threshold is reached. Eventually, 
however, tau may be further subjected to hyper-phosphorylation as a consequence of disease 
progression. Such a fluctuating pattern of tau phosphorylation has been observed in vitro 
(Liang, et al. 2009; LoPresti and Konat 2001). Prolonged tau-1IR neuritic bead accumulation 
in vitro, beyond the timeframe allowable for cultured primary neurons, may be required for 
impaired PP2A function, tau re-phosphorylation, and accumulation of more mature tau 
aggregates.
The notion that dephosphorylated tau (at the tau-1 epitope) could be linked to tau pathology 
is plausible. Dephosphorylated tau is known to associate with the neuronal membrane 
(Arrasate, et al. 2000; Maas, et al. 2000; Pooler, et al. 2012). The close proximity of tau to 
the membrane could facilitate Fyn-mediated activation of NRs and increased intracellular 
calcium accumulation. Although tau-1 immunoreactivity is rarely assessed as a pathological 
marker per se in mouse and human tissues, we detected tau-1-positive structures as distinct 
clusters in aged mice, LPS-treated mice, and human AD brain, consistent with a potential 
role for the tau-1IR species in tau pathogenesis (Figure 4). Whether the age-related tau-1IR 
pathology identified in this study is linked to primary age-related tauopathy (PART) recently 
described in humans is not clear, but there are intriguing parallels, as both phenomenon 
show clear age-related tau deposition in the hippocampus (Crary, et al. 2014).
We have begun to elucidate the biochemical properties of tau-1IR structures; they are 
enriched with oligomeric, acetylated, and hypo-phosphorylated tau at many AD-relevant 
epitopes analyzed. We have not detected robust misfolded tau epitopes (MC1 or Alz-50) or 
prominent amyloid conformation within tau beaded structures. Future studies could establish 
whether other brain pathologies including TDP-43 or Aβ facilitate endogenous tau-1IR 
pathology, which we cannot currently exclude. Lastly, tau-1IR beading in vitro appears to be 
reversible upon removal of Aβ-CM. Thus, tau-1IR neuritic beads may represent a feature of 
neuronal vulnerability that is amenable to pharmacological intervention. Taken together, our 
study highlights a mechanism linking neuroinflammatory stress to HDAC6-mediated 
neuritic tau accumulation, which we anticipate will provide insights into normal endogenous 
tau regulation, excitotoxic disease mechanisms, and avenues for therapeutic interventions in 
AD.
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Experimental Procedures
Double-label Immunofluorescence
Primary cortical neurons were grown on PDL-coated coverslips and cultured as described 
above and treated for indicated times. Cells were fixed in 4 % paraformaldehyde for 15 min, 
rinsed three times in PBS and permeabilized with 0.2 % Triton X-100 (Sigma) in PBS for 10 
min. Cells were then blocked in 2% milk for 1 h, and subsequently incubated with primary 
antibodies of interest overnight at 4°C. Cells were washed in PBS and incubated wit 
Alexi-488 or 594-conjugated secondary antibody. Cells were analyzed using an Olympus 
IX83 Inverted Microscope. The ratio of colocalization with Tau-1 was quantified by the 
number of beads that contain immunoreactivity from both Tau-1 and the antibody of interest 
among the total number of Tau-1 positive beads, using > 5 fields, and the sampling error was 
calculated using S.E.M. Statistical analysis was determined using a two-tailed unpaired 
Student’s t-test with unequal variance (significance set as P-value <0.05). All quantitative 
fluorescence was independently validated with a minimum of 3 different biological 
replicates. Primary antibodies used for immunofluorescence are listed in Table S1.
Live Calcium Imaging
Neuronal cultures were washed in HEPES-buffered artificial CSF (aCSF, concentrations in 
mM: NaCl 137, KCl 5, CaCl2 2.3, MgCl2 1.3, glucose 20, HEPES 10, pH 7.4) and 
preloaded with the calcium indicator, Fluo-4 AM using the Molecular Probes Fluo-4 NW 
Assay Kit (Molecular Probes/Invitrogen) at a 1:4 dilution. After 30 min, cultures were 
washed in aCSF and 18 mm coverslips mounted in a specialized stage for imaging (Warner 
Instruments). Images were captured on an Olympus IX71 inverted microscope at a 
temperature of 25°C which provided stable background activity for at least 2 h. TBST was 
added to the coverslips 3 h prior to the challenge, while MARK2 inhibitor, 39621 
(Millipore), AP5, and MMP-9 inhibitor (Calbiochem) were added 30 min prior to the 
challenge. The cells were challenged with CM (from hMDM or mouse microglia) at a 1:4 
dilution, MMP-9 (50 ng/mL) or MMP-7 (150 ng/mL). Time-lapse digital images were 
captured automatically by the Metamorph System (Molecular Device). Three pre-
stimulation measurements were taken to establish basal levels of fluorescence at the 
beginning of each experiment. Acute changes in calcium were measured at 0.1 min intervals 
for 6 min. Delayed changes in calcium were measured at 1 min intervals for an additional 1 
h. The increase in calcium intensity (free calcium) within each cell was then measured 
relative to the baseline measurements to correct for cell to cell differences in dye loading and 
intrinsic fluorescence. Control cultures were stimulated with aCSF in the same fashion to 
establish normal baseline calcium activity as well as any intrinsic toxic activity from the 
cortical neuron cultures. Spikes were evaluated compared with the control cultures. Calcium 
spiking frequency was calculated as the number of spikes per 100 images.
Statistical analysis
Graphpad Prism software was used for all statistical analysis. Results were pooled from a 
minimum of three independent experiments and presented as average ± standard error of the 
mean (SEM). Comparisons between two groups were analyzed using unpaired student t test. 
Significance was presented with *, **, or *** corresponding to p-value <0.05, p value 
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<0.01, or p value <0.001. Hippocampal regions with tau-1 immunoreactive (tau-1IR) clusters 
from at least N=3 mice per age group were thresholded using Metamorph software and tau-1 
intensity was plotted as the overall tau-1IR density per hippocampal region. Three isolated 
regions were chosen at random within the areas comprising tau-1IR clusters. Sections from 
HDAC6 KO mice that lacked tau-1IR clusters were used as negative controls to account for 
background staining intensity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Aβ-oligomer induced secretion of neuroinflammatory factors promotes endogenous 
neuritic tau beading in primary neurons
(A) Primary cortical neurons were exposed to Aβ oligomers (AβO, 1 μM) or a 1:4 dilution 
of microglia-derived (mAβ-CM) or hMDM-derived (Aβ-CM) conditioned media for 5 h 
followed by fluorescent microscopy analysis using the dephosphorylation-specific tau-1 
antibody, phospho-tau AT8 antibody, or total mouse tau antibodies T49, tau-5, and K9JA 
(green). Scale bar = 50 μm.
(B) Quantification of beads formed per 104 μm2 indicated hMDM-derived Aβ-CM increased 
neuritic tau bead formation, while direct addition of AβO alone did not significantly alter 
bead formation. Error bars indicate S.E.M (***, p-value < 0.001).
(C–H) Primary cortical neurons were treated with Aβ-CM at a 1:4 dilution for 5 h and were 
analyzed by double-labeling with tau-1 antibody (green) in combination with ac-K280 (C), 
pS199 (D), pS262 (E), pMARK2 (F), or tau T22 oligomer antibodies (G) (red). Co-
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localization of tau-1 immunoreactive foci with the indicated antibodies is highlighted by 
arrowheads in the inset.
(H) Quantification of co-localization was determined as percent of tau-1 co-localization per 
total number of tau-1-positive foci. Error bars indicate S.E.M.
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Figure 2. Depletion or inhibition of the deacetylase HDAC6 suppresses endogenous neuritic tau 
beading
(A–E) Wild-type or HDAC6 KO cortical neurons treated with Aβ-CM were double-labeled 
with tau-1 (green) in combination with HDAC6 (A, B), ac-K280 (C), CHIP (D) or FYN (E) 
(red). Scale bar = 50 μm.
(F) Quantification of beads formed per 104 μm2 indicated significantly decreased neuritic 
bead formation in HDAC6 KO neurons and TBST-treated wild-type neurons (see also Figure 
S5).
(G) Neuronal viability assays (LDH, MTT assays) were performed on primary cortical 
neurons treated with Aβ-CM in the absence or presence of TBST, which alleviated 
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neurotoxicity by LDH assay but did not affect metabolic activity detected by the MTT assay. 
Error bars indicate S.E.M (ns = not significant; *, p-value < 0.05; ***, p-value < 0.001).
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Figure 3. Aβ-oligomer induced neuroinflammatory stress promotes calcium dysfunction in an 
HDAC6-dependent manner
(A) Live calcium imaging using the calcium indicator Fluo-4 AM was performed on primary 
cortical neurons challenged with Aβ-CM in the absence or presence of TBST or the NR 
antagonist AP5. Scale bar = 50 μm.
(B) Exposure to Aβ-CM or mAβ-CM promoted gradual intracellular calcium increases (as 
detected by fluorescence intensity) that was potently suppressed by loss or inhibition of 
HDAC6 (HDAC6 KO or TBST) or by pre-treatment with the NR inhibitor AP5.
(C) The final delayed phase calcium increase is shown in wild-type or HDAC6 KO neurons 
pre-treated with MARK inhibitor 39621, TBST or AP5 (***, p-value < 0.001).
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Figure 4. Neuritic tau-1IR clusters accumulate in vivo during aging or neuroinflammatory stress
(A) Young (6-month) or old (27-month) wild type mouse brains were analyzed by confocal 
microscopy using the tau-1 antibody (green). The full hippocampus is depicted. Aged mice 
showed large tau-1-positive aggregates and clusters throughout the CA1 and other 
hippocampal regions as well as select cortical brain regions.
(B) Immunoblotting analysis of mouse hippocampal homogenates depicting tau-1 
immunoreactivity in young and aged mice.
(C–D) CA1 regions of aged wild type mice from 3 to 19 months old were analyzed by 
confocal microscopy or immunohistochemistry (D) to detect tau-1IR pathology. Tau-1IR foci 
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(green) started to accumulate in the hippocampus after 6 months. By 12 months, more 
detectable and widespread tau-1IR pathology was observed. Scale bar, 50 μm.
(E) Tau-1IR clusters were quantified in young vs. old mice. Error bars indicate S.E.M. ns = 
not significant; *, p-value < 0.05; **, p-value < 0.01. Scale bar = 100 μm.
(F–G) Saline control or LPS injected 3 month old wild-type mice were analyzed 10 months 
post injection and tau-1IR clusters in the hippocampus were quantified (G). Scale bar = 50 
μm.
Tseng et al. Page 24
Cell Rep. Author manuscript; available in PMC 2017 August 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. Acetylated oligomeric tau-1IR clusters develop in aged wild-type mice and are reduced 
in HDAC6 KO mice
(A) Aged wild-type mouse brains were double-labeled with tau-1 (green) in combination 
with MAP2, ac-K280, or T22 antibodies (red) and hippocampal regions were imaged by 
confocal microscopy. Prominent regions of co-localization are highlighted by arrowheads 
(depicting large single aggregates) and multi-aggregated tau-1IR clusters are highlighted 
within the dashed white circles. Scale bar = 50 μm.
(B) WT and HDAC6 KO mice (12 month old) were analyzed by double-labeling 
immunofluorescence to detect tau-1IR pathology (green) as well as dendritic tau 
mislocalization (MAP2, red) in the hippocampus. Scale bar = 50 μm
(C) Quantification of tau-1IR beads per hippocampus was determined from WT and HDAC6 
KO mice (n=5 mice for each genotype; *, p-value < 0.05).
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Figure 6. Dephosphorylated tau-1IR pathology is detected in human AD brain
(A) Cortical brain sections from human AD patients were analyzed by double-labeling using 
tau-1, AT8, or 6E10 antibodies along with Thioflavin S (ThS) to label AD pathology. The 
double-labeling illustrates tau-1IR immunoreactivity associated with ThS (white arrows). 
Scale bar = 50 μm.
(B) Biochemical fractionation of frontal cortex gray matter was performed and analyzed by 
immunoblotting using the indicated tau antibodies. Tau immunoreactivity was quantified 
from soluble (high-salt extracted) and insoluble (urea extracted) fractions using ImageQuant 
v8.1 and differences are represented as fold change compared to control non-AD samples. ns 
= not significant; *, p-value < 0.05; **, p-value < 0.01.
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Figure 7. Mass spectrometry profiling of the Aβ-oligomer induced secretome identified MMP-9 
as a regulator of neuritic tau beading
(A) A volcano plot of LC-MS/MS data generated from the secretome analysis of untreated 
or Aβ oligomer-treated hMDM. Relative protein abundance was plotted on the x-axis as log2 
ratios. Negative log10 transformed p-values were plotted on the y-axis. Significant protein 
hits (p-value < 0.05) are represented by green (up-regulated) and blue circles (down-
regulated). MMP-1, -7 and -9 were significantly altered, as indicated by red circles in the 
volcano plot. The proteins on the far left and right sides were only identified in either 
untreated (left) or Aβ oligomer-treated hMDM (right).
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(B) Top protein biological processing categories obtained with the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) are highlighted from Aβ oligomer-induced 
secretome.
(C) Zymography analysis and immunoblotting showed the presence of secreted and active 
MMP-9 in Aβ-CM.
(D) Primary cortical neurons treated with MMP-7 or MMP-9 overnight were analyzed by 
confocal microscopy with the tau-1 antibody (green) revealing MMP-9-mediated neuritic 
bead formation. Scale bar = 50 μm.
(E) Live calcium imaging of primary cortical neurons challenged with purified recombinant 
MMP-7 or MMP-9 in the absence or presence of TBST or AP5. MMP-9 treatment resulted 
in distinct calcium spiking intensities in a subset of neurons that was suppressed by TBST. 
Calcium spiking frequency was quantified as total calcium spikes and is reported as spiking 
per 100 frames. Error bars indicate S.E.M.
(F) Aβ-CM was pre-incubated with an MMP-9 specific inhibitor prior to addition to neurons 
for subsequent live calcium imaging. The acute calcium rise in response to Aβ-CM was 
significantly suppressed by MMP-9 inhibition alone (**, p-value < 0.01; ***, p-value < 
0.001).
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